NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.
- Published In:
- Neurobiology of disease, 56, 79-94 (2013)
- Authors:
- Jouroukhin, Yan, Ostritsky, Regina, Assaf, Yaniv, Pelled, Galit, Giladi, Eliezer, Gozes, Illana
- Database ID:
- RPEP-02205
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02205APA
Jouroukhin, Yan; Ostritsky, Regina; Assaf, Yaniv; Pelled, Galit; Giladi, Eliezer; Gozes, Illana. (2013). NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.. Neurobiology of disease, 56, 79-94. https://doi.org/10.1016/j.nbd.2013.04.012
MLA
Jouroukhin, Yan, et al. "NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.." Neurobiology of disease, 2013. https://doi.org/10.1016/j.nbd.2013.04.012
RethinkPeptides
RethinkPeptides Research Database. "NAP (davunetide) modifies disease progression in a mouse mod..." RPEP-02205. Retrieved from https://rethinkpeptides.com/research/jouroukhin-2013-nap-davunetide-modifies-disease
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.